1	Ciba-Geigy	_	NNP	_	_	6	SBJ	_	_
2	Ltd.	_	NNP	_	_	1	POSTHON	_	_
3	and	_	CC	_	_	1	COORD	_	_
4	Chiron	_	NNP	_	_	3	CONJ	_	_
5	Corp.	_	NNP	_	_	4	POSTHON	_	_
6	said	_	VBD	_	_	0	ROOT	_	_
7	they	_	PRP	_	_	8	SBJ	_	_
8	extended	_	VBD	_	_	6	OBJ	_	_
9	their	_	PRP$	_	_	10	NMOD	_	_
10	offer	_	NN	_	_	8	OBJ	_	_
11	for	_	IN	_	_	10	NMOD	_	_
12	Connaught	_	NNP	_	_	13	NAME	_	_
13	BioSciences	_	NNP	_	_	11	PMOD	_	_
14	Inc.	_	NNP	_	_	13	POSTHON	_	_
15	,	_	,	_	_	10	P	_	_
16	valued	_	VBN	_	_	10	APPO	_	_
17	at	_	IN	_	_	16	ADV	_	_
18	866	_	CD	_	_	19	DEP	_	_
19	million	_	CD	_	_	21	NMOD	_	_
20	Canadian	_	JJ	_	_	21	NMOD	_	_
21	dollars	_	NNS	_	_	17	PMOD	_	_
22	(	_	(	_	_	23	P	_	_
23	US$	_	$	_	_	21	PRN	_	_
24	736	_	CD	_	_	23	DEP	_	_
25	million	_	CD	_	_	23	DEP	_	_
26	)	_	)	_	_	23	P	_	_
27	to	_	TO	_	_	8	DIR	_	_
28	Oct.	_	NNP	_	_	27	PMOD	_	_
29	27	_	CD	_	_	28	NMOD	_	_
30	.	_	.	_	_	6	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	companies	_	NNS	_	_	4	SBJ	_	_
3	earlier	_	RBR	_	_	4	TMP	_	_
4	said	_	VBD	_	_	0	ROOT	_	_
5	they	_	PRP	_	_	6	SBJ	_	_
6	did	_	VBD	_	_	4	OBJ	_	_
7	n't	_	RB	_	_	6	ADV	_	_
8	want	_	VB	_	_	6	VC	_	_
9	to	_	TO	_	_	8	OPRD	_	_
10	raise	_	VB	_	_	9	IM	_	_
11	their	_	PRP$	_	_	12	NMOD	_	_
12	offer	_	NN	_	_	10	OBJ	_	_
13	to	_	TO	_	_	10	PRP	_	_
14	match	_	VB	_	_	13	IM	_	_
15	a	_	DT	_	_	17	NMOD	_	_
16	rival	_	JJ	_	_	17	NMOD	_	_
17	bid	_	NN	_	_	14	OBJ	_	_
18	by	_	IN	_	_	17	NMOD	_	_
19	Institut	_	NNP	_	_	20	NAME	_	_
20	Merieux	_	NNP	_	_	18	PMOD	_	_
21	S.A.	_	NNP	_	_	20	POSTHON	_	_
22	of	_	IN	_	_	17	NMOD	_	_
23	C$	_	$	_	_	22	PMOD	_	_
24	37	_	CD	_	_	23	NMOD	_	_
25	a	_	DT	_	_	26	NMOD	_	_
26	share	_	NN	_	_	23	ADV	_	_
27	,	_	,	_	_	23	P	_	_
28	or	_	CC	_	_	23	COORD	_	_
29	C$	_	$	_	_	28	CONJ	_	_
30	942	_	CD	_	_	29	DEP	_	_
31	million	_	CD	_	_	29	DEP	_	_
32	.	_	.	_	_	4	P	_	_

1	But	_	CC	_	_	3	DEP	_	_
2	they	_	PRP	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	the	_	DT	_	_	7	NMOD	_	_
5	C$	_	$	_	_	7	NMOD	_	_
6	30-a-share	_	JJ	_	_	5	AMOD	_	_
7	bid	_	NN	_	_	16	SBJ	_	_
8	,	_	,	_	_	7	P	_	_
9	which	_	WDT	_	_	10	SBJ	_	_
10	was	_	VBD	_	_	7	NMOD	_	_
11	due	_	JJ	_	_	10	PRD	_	_
12	to	_	TO	_	_	11	AMOD	_	_
13	expire	_	VB	_	_	12	IM	_	_
14	Monday	_	NNP	_	_	13	TMP	_	_
15	,	_	,	_	_	7	P	_	_
16	may	_	MD	_	_	3	OBJ	_	_
17	still	_	RB	_	_	16	TMP	_	_
18	be	_	VB	_	_	16	VC	_	_
19	extended	_	VBN	_	_	18	VC	_	_
20	or	_	CC	_	_	19	COORD	_	_
21	varied	_	VBN	_	_	20	CONJ	_	_
22	.	_	.	_	_	3	P	_	_

1	Merieux	_	NNP	_	_	12	SBJ	_	_
2	,	_	,	_	_	1	P	_	_
3	a	_	DT	_	_	5	NMOD	_	_
4	vaccine	_	NN	_	_	5	NMOD	_	_
5	manufacturer	_	NN	_	_	1	APPO	_	_
6	based	_	VBN	_	_	5	APPO	_	_
7	in	_	IN	_	_	6	LOC	_	_
8	Lyon	_	NNP	_	_	7	PMOD	_	_
9	,	_	,	_	_	8	P	_	_
10	France	_	NNP	_	_	8	APPO	_	_
11	,	_	,	_	_	8	P	_	_
12	is	_	VBZ	_	_	0	ROOT	_	_
13	51%-held	_	JJ	_	_	12	PRD	_	_
14	by	_	IN	_	_	13	AMOD	_	_
15	French	_	JJ	_	_	17	NMOD	_	_
16	state-owned	_	JJ	_	_	17	NMOD	_	_
17	Rhone-Poulenc	_	NNP	_	_	14	PMOD	_	_
18	S.A	_	NNP	_	_	17	POSTHON	_	_
19	.	_	.	_	_	12	P	_	_

1	Ciba-Geigy	_	NNP	_	_	2	SBJ	_	_
2	is	_	VBZ	_	_	0	ROOT	_	_
3	a	_	DT	_	_	6	NMOD	_	_
4	major	_	JJ	_	_	6	NMOD	_	_
5	pharmaceutical	_	JJ	_	_	6	NMOD	_	_
6	concern	_	NN	_	_	2	PRD	_	_
7	based	_	VBN	_	_	6	APPO	_	_
8	in	_	IN	_	_	7	LOC	_	_
9	Basel	_	NNP	_	_	8	PMOD	_	_
10	,	_	,	_	_	9	P	_	_
11	Switzerland	_	NNP	_	_	9	APPO	_	_
12	.	_	.	_	_	2	P	_	_

1	Chiron	_	NNP	_	_	7	SBJ	_	_
2	,	_	,	_	_	1	P	_	_
3	another	_	DT	_	_	5	NMOD	_	_
4	pharmaceutical	_	JJ	_	_	5	NMOD	_	_
5	concern	_	NN	_	_	1	APPO	_	_
6	,	_	,	_	_	1	P	_	_
7	is	_	VBZ	_	_	0	ROOT	_	_
8	based	_	VBN	_	_	7	VC	_	_
9	in	_	IN	_	_	8	LOC	_	_
10	Emeryville	_	NNP	_	_	9	PMOD	_	_
11	,	_	,	_	_	10	P	_	_
12	Calif	_	NNP	_	_	10	APPO	_	_
13	.	_	.	_	_	7	P	_	_

1	Connaught	_	NNP	_	_	2	SBJ	_	_
2	is	_	VBZ	_	_	0	ROOT	_	_
3	a	_	DT	_	_	5	NMOD	_	_
4	biotechnology	_	NN	_	_	5	NMOD	_	_
5	research	_	NN	_	_	2	PRD	_	_
6	and	_	CC	_	_	5	COORD	_	_
7	vaccine	_	NN	_	_	9	NMOD	_	_
8	manufacturing	_	NN	_	_	9	NMOD	_	_
9	concern	_	NN	_	_	6	CONJ	_	_
10	.	_	.	_	_	2	P	_	_

1	Institut	_	NNP	_	_	2	NAME	_	_
2	Merieux	_	NNP	_	_	4	NMOD	_	_
3	's	_	POS	_	_	2	SUFFIX	_	_
4	bid	_	NN	_	_	8	SBJ	_	_
5	for	_	IN	_	_	4	NMOD	_	_
6	Toronto-based	_	JJ	_	_	7	NMOD	_	_
7	Connaught	_	NNP	_	_	5	PMOD	_	_
8	has	_	VBZ	_	_	0	ROOT	_	_
9	run	_	VBN	_	_	8	VC	_	_
10	into	_	IN	_	_	9	DIR	_	_
11	problems	_	NNS	_	_	10	PMOD	_	_
12	with	_	IN	_	_	11	NMOD	_	_
13	the	_	DT	_	_	15	NMOD	_	_
14	Canadian	_	JJ	_	_	15	NMOD	_	_
15	government	_	NN	_	_	12	PMOD	_	_
16	,	_	,	_	_	15	P	_	_
17	which	_	WDT	_	_	18	SBJ	_	_
18	told	_	VBD	_	_	15	NMOD	_	_
19	Merieux	_	NNP	_	_	18	OBJ	_	_
20	last	_	JJ	_	_	21	NMOD	_	_
21	week	_	NN	_	_	18	TMP	_	_
22	that	_	IN	_	_	18	OBJ	_	_
23	it	_	PRP	_	_	24	SBJ	_	_
24	was	_	VBD	_	_	22	SUB	_	_
25	n't	_	RB	_	_	24	ADV	_	_
26	convinced	_	VBN	_	_	24	VC	_	_
27	that	_	IN	_	_	26	OBJ	_	_
28	the	_	DT	_	_	30	NMOD	_	_
29	proposed	_	JJ	_	_	30	NMOD	_	_
30	acquisition	_	NN	_	_	31	SBJ	_	_
31	would	_	MD	_	_	27	SUB	_	_
32	be	_	VB	_	_	31	VC	_	_
33	of	_	IN	_	_	32	PRD	_	_
34	``	_	``	_	_	36	P	_	_
35	net	_	JJ	_	_	36	NMOD	_	_
36	benefit	_	NN	_	_	33	PMOD	_	_
37	''	_	''	_	_	36	P	_	_
38	to	_	TO	_	_	36	NMOD	_	_
39	Canada	_	NNP	_	_	38	PMOD	_	_
40	.	_	.	_	_	8	P	_	_

1	Merieux	_	NNP	_	_	2	NMOD	_	_
2	officials	_	NNS	_	_	3	SBJ	_	_
3	are	_	VBP	_	_	0	ROOT	_	_
4	expected	_	VBN	_	_	3	VC	_	_
5	to	_	TO	_	_	4	OPRD	_	_
6	meet	_	VB	_	_	5	IM	_	_
7	with	_	IN	_	_	6	ADV	_	_
8	federal	_	JJ	_	_	9	NMOD	_	_
9	officials	_	NNS	_	_	7	PMOD	_	_
10	in	_	IN	_	_	6	LOC	_	_
11	Ottawa	_	NNP	_	_	10	PMOD	_	_
12	today	_	NN	_	_	6	TMP	_	_
13	to	_	TO	_	_	6	PRP	_	_
14	discuss	_	VB	_	_	13	IM	_	_
15	the	_	DT	_	_	16	NMOD	_	_
16	decision	_	NN	_	_	14	OBJ	_	_
17	.	_	.	_	_	3	P	_	_

